Asthma is a chronic respiratory disease blocking the airways of the lungs because of the inflammation, mucus production, tighten of muscles. The general symptoms are coughing, wheezing, shortness of breath and/or chest tightness and majorly these symptoms are closely related to the physical activity. There are different types of asthma, exercise-induced bronchoconstriction(EIB), allergic asthma, occupational asthma, childhood asthma. Chronic Obstructive Pulmonary Disease (COPD) is also respiratory disease which causes obstructions and difficulty in breathing, the primary cause of COPD is tobacco smoking and chemical flumes, dust, air pollution are minor causes of the disease. Major symptoms are long lasting cough, mucus that comes out along with cough, shortness of breath.
The world COPD and asthma drugs market is expected to reach $50,359 million by 2022, growing at a CAGR of 3.7% from 2016 to 2022. Increase in prevalence of asthma and COPD, increase in world ageing population, technological advancement in the treatment of asthma and COPD, growth in initiatives implemented by the government and non-government associations for rise in health awareness play a pivotal role in the growth of the global COPD and asthma drug market. Stringent government regulatory requirement for the approval of COPD and asthma drug, patent expiry of branded hamper the market growth.
The world asthma and COPD drugs market is segmented based on disease and medication class and geography. On the basis of disease, the market is segmented into COPD and asthma. Based on medication class, the world asthma and COPD drug market is segmented into combination products, short acting beta agonists (SABA), long acting beta agonists (LABA), inhaled corticosteroids (ICS), leukotriene antagonists (LTA), anticholinergics and others. And geographically, the market is segmented into North America, Europe, Asia-Pacific, and LAMEA.
Key benefits
MARKET BY DISEASES
MARKET BY MEDICATION CLASS
MARKET BY GEOGRAPHY
KEY PLAYERS
Other players in the value chain include (profiles not included in the report)
CHAPTER 1 INTRODUCTION
1.1 Report description
1.2 Key benefits
1.3 Key market segments
1.4 Research methodology
1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1 CXO perspective
CHAPTER 3 MARKET OVERVIEW
3.1 Market definition and scope
3.2 Key findings
3.2.1 Top investment pockets
3.2.2 Top winning strategies
3.3 Porters five forces analysis
3.3.1 Bargaining power of buyers (High)
3.3.2 Bargaining power of suppliers (Low to Moderate)
3.3.3 Threat of new entrants (Low)
3.3.4 Threat of substitutes (High)
3.3.5 Intense competitive rivalry
3.4 Market dynamics
3.4.1 Drivers
3.4.1.1 Increasi in number of asthmatic and COPD patients worldwide
3.4.1.2 Increase in world ageing population
3.4.1.3 Technological advancement in the treatment of asthma and COPD drugs
3.4.1.4 Initiatives taken by various government associations to raise awareness about daignosis and management of asthma and COPD
3.4.1.5 Increasing number of products in the pipeline
3.4.2 Restraints
3.4.2.1 Stringent regulatory requirements for the approval and commercialization of asthma and COPD drugs
3.4.2.2 Asthma and COPD drugs show side effects
3.4.2.3 Asthma and COPD drug approval process is expensive and time-consuming
3.4.2.4 Patent expiry of asthma and COPD drugs
3.4.3 Opportunities
3.4.3.1 Inrtoduction of generic drugs of asthma and COPD drugs
3.5 Market share analysis, 2015
CHAPTER 4 GLOBAL ASTHMA AND COPD DRUGS MARKET, BY DISEASE
4.1 Overview
4.2 Asthma
4.2.1 Global prevalence
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast
4.3 COPD
4.3.1 Global prevalence
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast
CHAPTER 5 GLOBALASTHMA AND COPD DRUGS MARKET, BY MEDICATION CLASS
5.1 Overview
5.2 Combination Drugs
5.2.1 Market size and forecast
5.2.2 Seretide/Advair
5.2.3 Symbicort
5.2.4 Relvar/Breo Ellipta
5.2.5 Flutiform
5.2.6 Dulera
5.3 Leukotriene antagonists (LTA)
5.3.1 Market size and forecast
5.3.2 Singulair
5.4 Inhaled corticosteroids (ICS)
5.4.1 Market size and forecast
5.4.2 Qvar
5.4.3 Pulmicort
5.4.4 Aerospan
5.4.5 Flovent
5.5 Anticholinergics
5.5.1 Market size and forecast
5.5.2 Spiriva
5.6 Short acting beta agonists (SABA)
5.6.1 Market size and forecast
5.6.2 ProAir
5.6.3 Ventolin
5.7 Long acting beta agonists (LABA)
5.7.1 Market size and forecast
5.8 Others
5.8.1 Market size and forecast
CHAPTER 6 GLOBALASTHMA AND COPD DRUGS MARKET, BY GEOGRAPHY, 2015-2022
6.1 Overview
6.1.1 Market size and forecast
6.2 North America
6.2.1 Key market trends
6.2.2 Key growth factors and opportunities
6.2.3 Market size and forecast
6.2.4 U.S.: market size and forecast
6.2.5 Canada market size and forecast
6.2.6 Mexico: market size and forecast
6.3 Europe
6.3.1 Key market trends
6.3.2 Key growth factors and opportunities
6.3.3 Germany: market size and forecast
6.3.4 France market size and forecast
6.3.5 UK: market size and forecast
6.3.6 Italy market size and forecast
6.3.7 Rest of Europe: market size and forecast
6.4 Asia-Pacific
6.4.1 Key market trends
6.4.2 Key growth factors and opportunities
6.4.3 Market size and forecast
6.4.4 Japan: market size and forecast
6.4.5 China market size and forecast
6.4.6 India: market size and forecast
6.4.7 Rest of Asia-Pacific market size and forecast
6.5 LAMEA
6.5.1 Key market trends
6.5.2 Key growth factors and opportunities
6.5.3 Market size and forecast
6.5.4 Latin America: market size and forecast
6.5.5 Middle East market size and forecast
6.5.6 Africa: market size and forecast
CHAPTER 7 GLOBALASTHMA AND COPD DRUGS PIPELINE -2015
CHAPTER 8 COMPANY PROFILES
8.1 Boehringer Ingelheim International GmbH
8.1.1 Company overview
8.1.2 Operating business segments
8.1.3 Business performance
8.1.4 Key strategic moves & developments
8.2 Merck & Co., Inc.
8.2.1 Company overview
8.2.2 Operating business segments
8.2.3 Business performance
8.2.4 Key strategic moves & developments
8.3 GlaxoSmithKline PLC.
8.3.1 Company overview
8.3.2 Operating business segments
8.3.3 Business performance
8.3.4 Key strategic moves & developments
8.4 Novartis AG
8.4.1 Company overview
8.4.2 Operating business segments
8.4.3 Business performance
8.4.4 Key strategic moves & developments
8.5 AstraZeneca
8.5.1 Company overview
8.5.2 Operating business segments
8.5.3 Business performance
8.5.4 Key strategic moves & developments
8.6 F. Hoffmann-La Roche Ltd
8.6.1 Company overview
8.6.2 Operating business segments
8.6.3 Business performance
8.6.4 Key strategic moves & developments
8.7 Teva Pharmaceutical Industries Ltd.
8.7.1 Company overview
8.7.2 Operating business segments
8.7.3 Business performance
8.7.4 Key strategic moves & developments
8.8 Vectura Group plc.
8.8.1 Company overview
8.8.2 Operating business segments
8.8.3 Business performance
8.8.4 Key strategic moves & developments
8.9 Pfizer, Inc.
8.9.1 Company overview
8.9.2 Operating business segments
8.9.3 Business performance
8.9.4 Key strategic moves & developments
8.10 Abbott Laboratories
8.10.1 Company overview
8.10.2 Operating business segments
8.10.3 Business performance
8.10.4 Key strategic moves & developments
List of Figures
FIG. 1 TOP INVESTMENT POCKETS IN GLOBALASTHMA AND COPD DRUGS MARKET
FIG. 2 TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, 2014-2016
FIG. 3 PORTERS FIVE FORCES ANALYSIS OF GLOBALASTHMA AND COPD DRUGS MARKET
FIG. 4 TOP IMPACTING FACTORS: GLOBALASTHMA AND COPD DRUGS MARKET
FIG. 5 GLOBALASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2015 & 2022 (% SHARE)
FIG. 6 GLOBALASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 7 GLOBALASTHMA AND COPD DRUGS MARKET, BY GEOGRAPHY, 2015 & 2022 (% SHARE)
FIG. 8 COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 9 COPD DRUGS MARKET, BY GEOGRAPHY, 2015 & 2022 (% SHARE)
FIG. 10 SERETIDE/ADVAIT MARKET, 2014-2022 ($MILLION)
FIG. 11 SYMBICORT MARKET, 2014-2022 ($MILLION)
FIG. 12 RELVAR/BREO ELLIPTA MARKET, 2014-2022 ($MILLION)
FIG. 13 FLUTIFORM MARKET, 2014-2022 ($MILLION)
FIG. 14 FLUTIFORM MARKET, 2014-2022 ($MILLION)
FIG. 15 SINGULAIR MARKET, 2014-2022 ($MILLION)
FIG. 16 QVAR MARKET, 2014-2022 ($MILLION)
FIG. 17 PULMICORT MARKET, 2014-2022 ($MILLION)
FIG. 18 AEROSPAN MARKET, 2014-2022 ($MILLION)
FIG. 19 FLOVENT MARKET, 2014-2022 ($MILLION)
FIG. 20 SPIRIVA MARKET, 2014-2022 ($MILLION)
FIG. 21 PROAIR MARKET, 2014-2022 ($MILLION)
FIG. 22 PROAIR MARKET, 2014-2022 ($MILLION)
FIG. 23 U.S.: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 24 CANADA: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 25 MEXICO: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 26 GERMANY: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 27 FRANCE: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 28 UK: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 29 ITALY: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 30 REST OF EUROPE: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 31 JAPAN: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 32 CHINA: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 33 INDIA: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 34 REST OF ASIA-PACIFIC: ASTHMA AND COPD DRUGS DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 35 LATIN AMERICA: ASTHMA AND COPD DRUGSMARKET, 2014-2022 ($MILLION)
FIG. 36 MIDDLE EAST: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 37 AFRICA: ASTHMA AND COPD DRUGS MARKET, 2014-2022 ($MILLION)
FIG. 38 BOEHRINGER INGELHEIM: REVENUE, 2013-2015 ($MILLION)
FIG. 39 BOEHRINGER INGELHEIM: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
FIG. 40 BOEHRINGER INGELHEIM: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 41 MERCK: REVENUE, 2013-2015 ($MILLION)
FIG. 42 MERCK: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
FIG. 43 MERCK: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 44 GSK: REVENUE, 2013-2015 ($MILLION)
FIG. 45 GSK: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
FIG. 46 GSK: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 47 NOVARTIS: REVENUE, 2013-2015 ($MILLION)
FIG. 48 NOVARTIS: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
FIG. 49 NOVARTIS: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 50 ASTRAZENECA: REVENUE, 2013-2015 ($MILLION)
FIG. 51 ASTRAZENECA: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
FIG. 52 ASTRAZENECA: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 53 ROCHE: REVENUE, 2013-2015 ($MILLION)
FIG. 54 ROCHE: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
FIG. 55 ROCHE: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 56 TEVA: REVENUE, 2013-2015 ($MILLION)
FIG. 57 TEVA: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
FIG. 58 TEVA: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 59 VECTURA: REVENUE, 2013-2015 ($MILLION)
FIG. 60 PFIZER: REVENUE, 2013-2015 ($MILLION)
FIG. 61 PFIZER: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
FIG. 62 PFIZER: REVENUE, BY GEOGRAPHY, 2015 (%)
FIG. 63 ABBOTT: REVENUE, 2013-2015 ($MILLION)
FIG. 64 ABBOTT: REVENUE, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
FIG. 65 ABBOTT: REVENUE, BY GEOGRAPHY, 2015 (%)
List of Tables
TABLE 1 ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2014-2022 ($MILLION)
TABLE 2 ASTHMA AND COPD DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 3 COPD DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 4 ASTHMA AND COPD DRUGS MARKET, BY MEDICATION CLASS TYPE, 2014-2022 ($MILLION)
TABLE 5 COMBINATION DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 6 LTA DRUG MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 7 ICS DRUG MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 8 ANTICHOLINERGICS DRUG MARKET, BY GEOGRAPHY,
TABLE 9 2014-2022 ($MILLION)
TABLE 10 SABA DRUG MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 11 LABA DRUG MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 12 OTHER DRUGS MARKET, BY GEOGRAPHY, 2014-2022 ($MILLION)
TABLE 13 GLOBAL ASTHMA AND COPD DRUGS MARKET, BY GEOGRAPHY, 2015-2022 ($MILLION)
TABLE 14 NORTH AMERICA: ASTHMA AND COPD DRUGS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 15 NORTH AMERICA: ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2014-2022 ($MILLION)
TABLE 16 NORTH AMERICA: ASTHMA AND COPD DRUGS MARKET, BY MEDICATION CLASS, 2014-2022 ($MILLION)
TABLE 17 EUROPE: ASTHMA AND COPD DRUGS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 18 EUROPE: ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2014-2022 ($MILLION)
TABLE 19 EUROPE: ASTHMA AND COPD DRUGS MARKET, BY MEDICATION CLASS, 2014-2022 ($MILLION)
TABLE 20 ASIA-PACIFIC: ASTHMA AND COPD DRUGS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 21 ASIA-PACIFIC: ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2014-2022 ($MILLION)
TABLE 22 ASIA-PACIFIC: ASTHMA AND COPD DRUGS MARKET, BY MEDICATION CLASS, 2014-2022 ($MILLION)
TABLE 23 LAMEA: ASTHMA AND COPD DRUGS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 24 LAMEA: ASTHMA AND COPD DRUGS MARKET, BY DISEASE, 2014-2022 ($MILLION)
TABLE 25 LAMEA: ASTHMA AND COPD DRUGS MARKET, BY MEDICATION CLASS, 2014-2022 ($MILLION)
TABLE 26 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
TABLE 27 BOEHRINGER INGELHEIM: OPERATING SEGMENTS
TABLE 28 MERCK: COMPANY SNAPSHOT
TABLE 29 MERCK: OPERATING SEGMENTS
TABLE 30 GSK: COMPANY SNAPSHOT
TABLE 31 GSK: OPERATING SEGMENTS
TABLE 32 NOVARTIS: COMPANY SNAPSHOT
TABLE 33 NOVARTIS: OPERATING SEGMENTS
TABLE 34 ASTRAZENECA: COMPANY SNAPSHOT
TABLE 35 ASTRAZENECA: OPERATING SEGMENT
TABLE 36 ROCHE: COMPANY SNAPSHOT
TABLE 37 ROCHE: OPERATING SEGMENTS
TABLE 38 TEVA: COMPANY SNAPSHOT
TABLE 39 TEVA: OPERATING SEGMENTS
TABLE 40 VECTURA: COMPANY SNAPSHOT
TABLE 41 VECTURA: OPERATING SEGMENTS
TABLE 42 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
TABLE 43 PFIZER: OPERATING SEGMENTS
TABLE 44 ABBOTT: COMPANY SNAPSHOT
TABLE 45 ABBOTT: OPERATING SEGMENTS
Contact us at the Consulting WP office nearest to you or submit a business inquiry online.
Subscribe to Our Newsletter
Published On : December 2019
$ 3600
Published On : November 2019
$ 3600
Published On : October 2019
$ 2950
Published On : October 2019
$ 2950
Published On : October 2019
$ 2950
